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IMPORTANCE Amajor challenge for drug development in neurodegenerative diseases is that
adequately powered efficacy studies with meaningful end points typically require several
hundred participants and long durations. Prion diseases represent the archetype of brain
diseases caused by protein misfolding, the most common subtype being sporadic
Creutzfeldt-Jakob disease (sCJD), a rapidly progressive dementia. There is no
well-established trial method in prion disease.
OBJECTIVE To establish a more powerful andmeaningful clinical trial method in sCJD.
DESIGN, SETTING, AND PARTICIPANTS A stratifiedmedicine and simulation approach based on
a prospective interval-cohort study conducted fromOctober 2008 to June 2014. This study
involved 598 participants with probable or definite sCJD followed up over 470 patient-years
at a specialist national referral service in the United Kingdomwith domiciliary, care home, and
hospital patient visits. We fitted linear mixedmodels to the outcomemeasurements, and
simulated clinical trials involving 10 to 120 patients (no dropouts) with early to moderately
advanced prion disease using model parameters to compare the power of various designs.
MAIN OUTCOMES ANDMEASURES A total of 2681 assessments were done using a functionally
orientated composite end point (Medical Research Council Scale) and associated with clinical
investigations (brain magnetic resonance imaging, electroencephalography, and
cerebrospinal fluid analysis) andmolecular data (prion protein [PrP] gene sequencing,
PrPSc type).
RESULTS Of the 598 participants, 273 weremen. The PrP gene sequence was significantly
associated with decline relative to any other demographic or investigation factors. Patients
with sCJD and polymorphic codon 129 genotypes MM, VV, andMV lost 10% of their function
in 5.3 (95% CI, 4.2-6.9), 13.2 (95% CI, 10.9-16.6), and 27.8 (95% CI, 21.9-37.8) days,
respectively (P < .001). Simulations indicate that an adequately powered (80%; 2-sided
α = .05) open-label randomized trial using 50% reduction in Medical Research Council Scale
decline as the primary outcome could be conducted with only 120 participants assessed
every 10 days and only 90 participants assessed daily, providing considerably more power
than using survival as the primary outcome. Restricting to VV or MV codon 129 genotypes
increased power even further. Alternatively, single-arm intervention studies (half the total
sample size) could provide similar power in comparison to the natural history cohort.
CONCLUSIONS AND RELEVANCE Functional end points in neurodegeneration need not require
long and very large clinical studies to be adequately powered for efficacy. Patients with sCJD
may be an efficient and cost-effective group for testing disease-modifying therapeutics.
Stratified medicine and natural history cohort approaches may transform the feasibility of
clinical trials in orphan diseases.
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H umanpriondiseases are fatal neurodegenerative con-ditions,whichmayoccur sporadically, be inheritedbycodingmutation in the prion protein gene (PRNP), or
be acquired from iatrogenic or dietary exposure to prions.1
Approximately 90 to 120 people are diagnosed as having
prion disease each year in the United Kingdom.2 Sporadic
Creutzfeldt-Jakobdisease (sCJD) is themostcommonform(ap-
proximately85%)andthemostobvious target for clinical trials.
Typically, sCJD manifests as a rapidly progressive dementia
withmyoclonusandotherneurological signs.Themedianclini-
cal duration is approximately 4months, although formswith
short (few weeks) and long (>2 years) durations are well
recognized.3The fundamentalpathogenicprocess inpriondis-
ease is the conversion of host cellular prion protein (PrPC) to
abnormally foldedmultimeric forms (PrPSc andother disease-
related forms) by seeded polymerization, a process that is
thought tobewidely shared inneurodegeneration.4 Priondis-
easesareparticularly tractable fordrugdevelopment,withclear
target validation and availability of suitable cellular and ani-
malmodels. Indeed, laboratory animals are naturally suscep-
tible to prion infections, providing increased confidence that
therapeutics shown to be active in preclinical models may
translate to humans. Passive immunotherapywithmonoclo-
nal antibodies targeting PrPC has been shown to be effective
in mouse models,5 and humanized antibodies developed for
clinical trial6 and small-molecule therapeutics, which sup-
press prion replication and delay or prevent disease progres-
sion inmice,havebeen reported frommultiple laboratories.7-9
However, to our knowledge, there is no effective therapeutic
that has been shown to modify the course of the human
disease.
In response to the challenges faced during Medical Re-
search Council (MRC) PRION-110 and other human trials,11,12
including the lackofavalidatedoutcomemeasureandthepau-
city of natural history data, we have studiedUKpatientswith
prion disease to optimize clinical trialmethods anddevelop a
resource for open-label studies. Thisworkwasdone as part of
an ongoing prospective interval-cohort study, the National
PrionMonitoring Cohort (cohort study),which began recruit-
ing in 2008. In preparation for clinical trials in sCJD, we used
item-responsemodeling todevelopa functionallyoriented rat-
ing scale (MRCPrionDiseaseRating Scale, orMRCScale)with
favorable statistical properties andweighted the items to rep-
resent the most impactful domains reported by patients and
caregivers.13
Stratifiedmedicine involves identifyingstratawithinadis-
ease anddeepening theunderstandingof themechanismsun-
derpinning these strata. The purpose of this is to allow better
targetingof treatments to specific diseasepathways and iden-
tification of treatments effective for particular groups of pa-
tients to reduceheterogeneity and improve thepowerof clini-
cal trials. Here we took a stratified experimental medicine
approach inpriondiseasewith the aimofdetermining thekey
factors that are associatedwith functional decline in sCJDand
might be included in future clinical trial models from a wide
rangeofdemographic, clinical, genetic, investigation, andmo-
lecular parameters. A common amino acid polymorphism at
position 129 of the prion protein gene (PRNP) is the most im-
portant genetic susceptibility factor in prion disease and also
affects propagationof distinct humanprion strains by confor-
mational selection.4,14-16Acombinationofdiseaseetiology, se-
verity, and genetic stratificationwithPRNP codon 129proved
to be an extremely powerful approach in our trial model, re-
sulting in estimated sample sizes for adequately powered and
meaningful clinical trials,whichare substantially smaller than
those required in other more common neurodegenerative
diseases.
Methods
Patients
From 2004, UK neurologists were asked by the chiefmedical
officer of the Department of Health, England, to refer all pa-
tientswith suspectedpriondisease jointly to theNational CJD
ResearchandSurveillanceUnit and to theNationalHealthSer-
viceNationalPrionClinic.Communicationbetweenbothunits
several timesperweek ensures exchangeof patient details re-
ferred to oneof theunits. Eighty-five percent of patientswere
visited by the National Prion Clinic within 5 days of referral.
Details of enrollment into the PRION-1 Trial and cohort study
have been published.10,13 In brief, the cohort aimed to enroll
all symptomaticpatientswithpriondisease in theUnitedKing-
domincludingall patientswithprobableordefinite sCJD,vari-
ant CJD, iatrogenic CJD, and inherited prion disease, accord-
ing to updated diagnostic criteria.17 In addition, patients
thought to have prion disease but notmeeting formal criteria
could be enrolled following review by an expert panel. Pa-
tientswere enrolled at home, hospitals, and other health care
settings around the United Kingdom from 2008 onwards
(Figure 1). This current study was conducted from October
2008 to June 2014.
Consent and Ethics
Informed consent was obtained directly from study partici-
pants or fromrelatives, caregivers, or IndependentMental Ca-
pacity Advocates as appropriate. Ethical approval was ob-
tained fromtheScotlandAResearchEthicsCommittee (cohort)
or the Eastern Research Ethics Committee (PRION-1).
Key Points
Question: Can clinical trial methods in Creutzfeldt-Jakob disease
(CJD) be improved?
Findings:Use of everyday patient functions as a clinical trial
outcomewould make the finding of a therapeutic effect more
meaningful. Wemodeled repeatedmeasurements of theMedical
Research Council Scale in CJD after excluding severely affected
patients. The important determinant of the rate of deterioration in
function was the genotype at polymorphic codon 129 of the prion
protein gene. Using this genetic cofactor and frequent
telemeasurements, statistical power in simulated trials was
improved.
Meaning: Stratified medicine and natural history cohort
approaches may transform the feasibility of clinical trials in CJD.
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The eAppendix in the Supplement provides the stratifi-
cation and assessment schedule, molecular analysis, investi-
gations, statistical analysis, and details of trial simulations.
Results
Baseline Characteristics and Completion of Investigations
We chose broad enrollment criteria to ensure that the cohort
studywas representative of prion disease in the United King-
dom; enrollments through June 2014 are included in these
analyses (Table 1). Ninety-sevenpercent of eligible visitedpa-
tients joined thestudyand less than1%withdrewconsentprior
to death. A total of 2681 assessments were done over 470 pa-
tient-years of study. Diagnostic accuracy was very good, and
94%of those recruitedmet criteria for probable human prion
disease.Autopsywasdone in60%,whichconfirmedpriondis-
ease in all cases, and amolecular diagnosis by gene test or bi-
opsy was achieved in 22%, resulting in 70% with a definite
diagnosis overall.
Visualization of MRC Scale measurements showed dis-
tinct patterns of decline (Figure 2A) namely: (1) rapid decline
over weeks or a few months (mostly patients with sCJD, but
including some acquired prion disease and specific inherited
priondiseasemutations [stratum 1, eAppendix in the Supple-
ment]); (2) slow decline over years (almost exclusively pa-
tients with inherited prion disease typically associated with
the GSS phenotype [stratum 2, eAppendix in the Supple-
ment]); and (3) a small proportion of patients with rapid
decline followed by prolonged survival at high levels of neu-
rodisability, essentially a comatose state (MRCScale <3), plau-
sibly due to exceptional supportive care.
Figure 1. Flowchart of Enrollment and Selection of Patient Subset forMain Study
557 Enrolled107 Enrolled
919 Patients referred from the
National Prion Monitoring
Cohort study
244 Patients referred from the
PRION-1 study
20 Patients transferred a
644 Enrolled
598 Participants
348 Included by MRC Scale (≥5)
46 Excluded
41 Ineligible (did not have
prion disease) 
5 Withdrew consent
162 With sCJD or fast IPD included
in the final analysis
186 Excluded
20 With vCJD
12 With iCJD
59 With slow IPD
60 Asymptomatic
35 Controls
250 Excluded from main
analysis (MRC Scale <5)
362 Not enrolled
346 Ineligible 
50 Declined visit
211 Unlikely to have prion disease,
not visited
85 Died before enrollment visit
16 Eligible (did not consent)
137 Not enrolled
105 Ineligible 
20 Not confirmed as having prion
disease
37 At risk only, not yet diagnosed
32 Eligible
29 Did not consent
3 Died before enrollment visit
24 Died before screening visit
24 Judged terminal, not visited
iCJD indicates iatrogenic Creutzfeldt-Jakob disease; IPD, inherited prion disease; MRC, Medical Research Council; sCJD, sporadic Creutzfeldt-Jakob disease;
vCJD, variant Creutzfeldt-Jakob disease.
a Twenty patients were enrolled in the cohort study after PRION-1 was completed.
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The principal aim of this analysis was to establish a trial
model based on repeated measurements of the MRC Scale.
Therefore,weexcluded3groupsofpatients fromfurtheranaly-
ses. First, because sCJD is by far the most common category
of priondisease andgiven thevastlydifferent time scales over
which functional decline occurred in stratums 1 and 2
Table 1. Baseline Characteristics
Characteristic
Patients With MRC Scale <5 at Enrollment
Patients With MRC Scale ≥5 at Enrollment
Stratum 1 Stratum 2 Stratum 3
Included in Model Excluded From Model
sCJD vCJD iCJD Fast IPD Slow IPD sCJD Fast IPD vCJD iCJD Slow IPD Asymptomatic Control
Enrolled 217 6 4 15 8 147 15 20 12 59 60 35
Age at
enrollment,
median
(range), y
68
(46-88)
54
(26-56)
48
(27-51)
65
(54 -78)
47
(40-65)
65
(39-83)
55
(38-86)
25
(14-50)
46
(37-51)
46
(26-69)
39
(20-88)
47
(23-75)
Sex
Male 78 2 3 7 3 81 8 15 11 26 22 17
Female 139 4 1 8 5 66 7 5 1 33 38 18
Time between
enrollment
and first
symptoms,
median (IQR),
mo
3 (2-5)9 (7-22) 5 (3-12) 3 (2-4) 36 (16-51) 6 (3-9) 7 (4-12) 6 (5-11) 8 (5-12) 30 (14-62) NA NA
MRC Scale at
enrollment
[0-20]
No.
assessed
215 5 4 15 8 147 15 20 12 59 60 35
Median
(IQR)
1 (0-2)3 (2-4) 3 (2-4) 1 (0-2) 2 (1-2) 10 (7-14) 14 (10-19) 15 (11-18) 16 (12-18) 18 (12-19) 20 (20-20) 20 (20-20)
MMSE score
at enrollment
[0-30]
No.
assessed
164 1 3 13 5 124 14 19 12 54 56 35
Median
(IQR)
0 0 0 0 0 14 (6-20) 18 (14-27) 19 (14-23) 21 (17-28) 20 (15-28) 30 (29-30) 30 (30-30)
Rankin score
at enrollment
[0-5]
No.
assessed
216 5 4 15 8 146 15 19 12 58 58 35
Asymp-
tomatic (0)
0 0 0 0 0 0 0 0 0 3 56 35
No or slight
symptoms
(1/2)
0 0 0 0 0 10 3 2 4 18 1 0
Moderate
disability
(3)
0 0 0 0 0 31 6 6 1 23 0 0
Moderate
to severe
disability
(4)
7 2 0 2 1 73 4 10 6 11 0 0
Severe
disability
(5)
209 3 4 13 7 32 2 1 1 3 1 0
Median
(IQR)
5 5 (4-5) 5 5 5 4 (3-4) 3 (3-4) 4 (3-4) 4 (2-4) 3 (2-3) 0 0
Codon 129
No.
assessed
170 6 4 14 8 139 15 20 12 57 33 0
MM 113 6 1 13 4 46 9 19 2 32 21 …
MV 25 0 2 1 3 56 6 1 10 22 11 …
VV 32 0 1 0 1 37 0 0 0 3 1 …
Abbreviations: ellipses, no data available for this group; iCJD, iatrogenic
Creutzfeldt-Jakob disease; IPD, inherited prion disease; IQR, interquartile range;
MMSE, Mini-Mental State Examination; MRC, Medical Research Council; NA, not
applicable; sCJD, sporadic Creutzfeldt-Jakob disease; vCJD, variant
Creutzfeldt-Jakob disease.
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(Figure 2A),wedecided to focus on rapidly progressive forms
of prion disease, therefore excluding stratum 2. In stratum 1
patients, rates of decline were significantly slower for ac-
quired prion disease vs sCJD (P < .001). Second, because in-
cidence of acquired disease is currently very low, we ex-
cluded this etiological category from further analyses. As
rapidly progressive forms of inherited prion disease may not
bediagnosed for severalweeks after priondisease itself is first
identified, these patients were included, although certain
mechanisms of action of experimental therapeutics may re-
quire them to be excluded from a prospective clinical trial.
Third, becausemany patients are diagnosed as having CJD at
advanced stages of neurodisability, when irreversible neuro-
nal deathhas alreadyoccurred,we excludedpatientswith se-
vere disease at presentation (MRC Scale <5).
Rates ofMRC Scale Decline in Different Groups
Defined by Codon 129
In thebest-fitting linearmixedmodel in 154patientswith rap-
idly progressing prion disease (sCJD and fast-progressing in-
herited prion disease) (see eFigure 1 in the Supplement for
individual fits), baseline MRC Scale depended only on age,
being 4.1 Rasch units lower for every 10 years older (P < .008;
Table 2).18 Subsequent decline was strongly associated with
codon 129 genotype (interaction P < .001); predicted de-
clines from the best possible score of 100 (20/20 MRC Scale)
are shown inFigure2B.Patientswith sCJD/fast inheritedprion
disease and polymorphic codon 129 genotypes MM, VV, and
MV lost 10% of their function measured by the MRC Scale in
5.3 (95% CI, 4.2-6.9), 13.2 (95% CI, 10.9-16.6), and 27.8 (95%
CI, 21.9-37.8) days, respectively. There was no evidence that
codon 129genotype significantly affected theMRCScalemea-
surement at enrollment (in the finalmodeled sample,P = .11).
However, in addition to these population-level differences in
the mean declines, codon 129 genotype also significantly af-
fected how variable individual patients were around these
means (differential random effects and residual errors,
P < .001). Although enrollment scores varied similarly be-
tween MM and non-MM genotype patients, subsequent de-
clines varied significantly more in MM than non-MM, and
residual errors (variabilitynot explainedby theunderlying tra-
jectories) were also significantly greater (Table 2).
Once the main model had been constructed and the po-
tential effects of enrollment function, age, sex, disease cat-
egory, and codon 129 had been considered, we went on to
explore whether the following additional investigation
factors had important effects on baseline or decline in MRC
Scale: clinical phenotype as assessed by the visiting physi-
cian (7 types, sCJD only; eAppendix in the Supplement); the
presence or absence of signal change in the basal ganglia, cor-
tex, or thalamus on brainmagnetic resonance imaging (MRI);
molecular strain type (PrPSc types 1-3 using the London
classification19); the presence of periodic sharp wave com-
plexes or background abnormalities on routine electroen-
cephalographic recordings; the presence or absence of 14-3-3
protein in routinecerebrospinal fluid (CSF)analysis;or thecon-
centration of CSF S100b (eTable in the Supplement). Four of
these factors affected decline in MRC Scale when considered
alone (clinical category; n = 159; P < .001), molecular strain
type20 (n = 63; P = .03), periodic sharp wave complexes
(n = 147;P = .009),andCSFS100b(n = 124;P = .046),buteither
theseeffectsdisappearedafter adjusting for theeffectof codon
129 subtype on decline (periodic sharp wave complexes; ad-
justedP = .33)or effectsweakenedwith theeffectof codon129
subtyperemainingsimilar toTable2andmuchstronger inmag-
nitude. In themultivariateanalysis,higher levelsofCSFS100b,
a quantitative measurement of a glial protein routinely used
to assist diagnosis ofCJD,were associatedwithmore rapidde-
cline (P = .005), althoughnot at a statistical level beyond that
whichmightbeexpectedasa result ofperforming testsofmul-
tiple hypotheses. Therefore, the PrP gene sequence appears
Figure 2. Spaghetti Plots and Graph of Rasch Score
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A, Spaghetti plots showing changes from baseline over time in all cohort
patients. Individual patient trajectories are shown for sporadic
Creutzfeldt-Jakob disease (CJD), acquired CJD, and inherited prion disease
(IPD). This chart prompted initial decisions about patient selection for
modeling: slowly progressive IPD and acquired CJDwere excluded as were
serial measurements of theMedical Research Council (MRC) Scale less than 3
(see the Baseline Characteristics and Completion of Investigations section). The
vertical gap represents a change in the time scale (x-axis). B, Predicted
neurological declines from best possible score by codon 129 subtype. This chart
showsmodel-predictedmean declines (lines) and 95% CIs (bands) in stratum 1
patients with 3 different codon 129 genotypes at PRNP. The Rasch score
approximates to 5 times theMRC Scale in Figure 2A.
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to be a profoundly important predictor of decline relative to
other demographic or investigation factors.
Power Calculations Using theMRC Scale
Weused theobservedenrollment frequencyof codon 129 sub-
types (33% MM, 43% MV, and 24% VV), distribution of ages
(mean [SD], 65.1 [9.4] years), and population and individual
rates of decline as estimated in Table 2 to simulate cohorts of
patientswhomight be enrolled into clinical trials of an inves-
tigational agent that reduced the rate of decline by (propor-
tionately) 0%, 25%, or 50%. We assumed a fixed percentage
reduction indecline given the large absolutedifferences inde-
cline observed (Table 2); therefore,we estimated the effect of
the interventionusing a test for thepercentage reduction (see
the eAppendix in the Supplement for details). We compared
the power of different sized trials to detect effects, based on
estimating the effect of an intervention on theMRCScale and
survival.
First, we considered a randomized trial (which could be
either placebo controlled or open label, although thepossibil-
ityof reportingbias inanopen-label trialwouldneedtobecare-
fully considered). Figure 3A shows the power of such a trial,
witha total of 50 to 120 fast-progressingpatients (MM,MV,and
VV) randomized 1:1 control to intervention, and assessed ev-
ery 10days, to detect a 25%or 50%reduction indecline in the
MRC Scale. A total of 120 patients would need to be random-
ized to provide 80% power to detect a 50% reduction in de-
cline; the samenumberof patients provides 5%to 10%greater
power fromusing the repeatedMRCScalemeasurements than
a survival end point on the same population.
The MRC Scale requires only 2 minutes to acquire over
the telephone and is highly acceptable to patients and their
caregivers: therefore, we considered the effect of more fre-
quent measurements on power (Figure 3B). The same power
as achieved with 120 randomized patients measured every
10 days could be achieved by 110 patients every 5 days, 100
patients thrice weekly, or 90 patients daily, as a conse-
quence of improved precision of estimation of rates of
decline. Therefore, power gains for daily measurement over
a survival end point were 13% to 20% for the same number
of patients.
Last, given the substantially greater variability observed
in rates of decline in theMM subgroup, we considered the ef-
fect on power of restricting a trial to different codon 129 sub-
types (Figure 3C). Because theVVsubgrouphave less variabil-
ity than the MM subgroup, but faster declines than the MV
subgroup,only40randomizedVVpatientsprovidedmorethan
80% power to detect 50% reductions in decline. However, at
the observed population frequencies, 40 VV patients would
beexpected fromacohort of 167patients in total,whichwould
have provided greater power overall.
An alternative approach would be a single-arm open-
label studywith comparisonsmade to the cohort natural his-
tory data. Such nonrandomized comparisons have well-
recognized limitations, the most important being changes in
external management. Simulations of an existing fixed co-
hort of 200 individuals tested once every 10 days with a new
cohort receiving treatment demonstrate that similar power
could be achieved with around half the randomized patients
(eFigure 2 in the Supplement).
Table 2. Model forMRC Scale Decline in Trial-Relevant Populationa
Factor Estimate (95% CI) P Value
P Value for
Heterogeneity/Interaction
vs Reference Category
Estimates of Baseline and Decline
Baseline, aged 65 y
MM 53.19 (47.82 to 58.55) NA NA
MV 57.88 (53.85 to 61.90) NA .17
VV 50.89 (45.60 to 56.18) NA .55
Per 10 y older at enrollment −4.12 (−7.14 to −1.10) .008 NA
Decline, per d
MM −1.90 (−2.36 to −1.45) <.001 NA
MV −0.36 (−0.83 to 0.11) <.001 <.001
VV −0.76 (−1.24 to −0.28) <.001 <.001
Estimates of Individual Variability
MM
Baseline 17.17 (13.31 to 22.17) NA NA
Decline 1.36 (0.95 to 1.95) NA NA
Correlation (baseline, decline) 0.38 (0.00 to 0.66) NA NA
Residual error 12.80 (10.91 to 15.02) NA NA
Non-MM
Baseline 14.75 (12.52 to 17.37) NA NA
Decline 0.33 (0.24 to 0.46) NA NA
Correlation (baseline, decline) 0.24 (−0.02 to 0.47) NA NA
Residual error 9.20 (8.57 to 9.87) NA NA
Abbreviations: MRC, Medical
Research Council; NA, not applicable.
a Model includes 824measurements
from 154 patients with sporadic
Creutzfeldt-Jakob disease and
patients with fast IPD in stratum 1
with MRC Scale of 5 or greater at
enrollment. Reference category
aged 65 years, MM.
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Discussion
In this study, we identified a key predictor of functional de-
cline in rapidly progressive forms of prion disease, codon 129
genotype,enablingus toassess thepotentialgains fromastrati-
fied medicine approach to future clinical trials. Through use
of natural history data collected in a prospective observa-
tional cohort study, we have optimized a clinical trial model
to increase power to detect clinically relevant effects on a
premortality end point measuring functional decline that is
judged highly relevant by patients and caregivers. Our 2 key
findings are, first, that genetic variation in the prion protein
gene has a profound influence on the rate of functional de-
cline in rapidlyprogressivehumanpriondisease and is, there-
fore, likely theessential factoronwhich tostratifya trialmodel.
Figure 3. Power for Different Sizes of Randomized Trial
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according to codon 129 subtype.
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Second, that a combination of factors, including the use of a
bespoke functionally orientated rating scale, the use of fre-
quent assessments by telemedicine, the rapidly progressive
nature of prion disease, and the stratification by codon 129,
contribute to the potential for remarkably powerful clinical
trials.
Despite the fact that codon 129 was known to be an
important modifier of susceptibility and phenotype of prion
diseases, we were surprised by the magnitude of the effects
we observed on functional decline after diagnosis. The
homotypic protein-protein interactions in patients with
PRNP homozygous prion disease may occur faster than het-
erotypic interactions in heterozygous individuals,14 result-
ing in more rapid propagation of prions and/or generation of
neurotoxic forms of abnormal PrP.21 Further, codon 129 is
known to be important in determining prion strain
selection.4 Prion strains, analogous to strains of bacteria or
viruses, are associated with distinct types of misfolded PrP
and distinct and transmissible clinicopathological features.
Therefore, it is likely that some of the distinction between
the rates of decline of codon 129 methionine and valine
homozygotes are related to strain selection by codon 129.
The PrPSc type, which is a measure of abnormal PrP confor-
mation and strain, did provide some limited additional
value beyond codon 129 alone but was only able to be mea-
sured in approximately 40% of the early and rapidly pro-
gressive CJD subset and always retrospectively after
autopsy, seriously limiting its use as a factor in clinical
trials. The lack of a detectable role of PrPSc type may relate
to the fact that this is highly correlated with codon 129
genotype and that, while the autopsy rate in the study was
high, many patients were alive at the data freeze and miss-
ing data remain substantial. We note that variation in the
slopes of decline of codon 129 methionine homozygous
patients was greater than for other genotypes, suggesting
that strain diversity/permissibility may be greatest in this
genotype.
The last decade has seen the advent of genome-wide
technologies that have driven the discovery of many risk
factors in neurodegeneration.22 Although examples are
emerging,23 phenotypic heterogeneity is less well under-
stood, in part because the imperative to study large sample
sizes has come at the expense of well-characterized clinical
cohorts. Clinical trials in common neurodegenerative dis-
eases do not typically stratify by genetic factors. One excep-
tion is APOE in some studies of Alzheimer disease immuno-
therapy, although this decision was primarily driven by an
increased susceptibility to amyloid-related imaging abnor-
malities in APOE4 carriers.24 The potent genetic effects we
observed in this study suggest the potential of using genetic
modifiers to improve power in clinical trials in neurodegen-
eration more widely.
There were some limitations of this study. A concern
about avoiding making a diagnostic error, and a sense that it
was only important to diagnose treatable disorders, means
that referral to specialist centers often occurs late in the
clinical course of human prion disease, when confirmatory
tests are complete. Consequently, most patients enrolled in
our cohort study had advanced neurodisability at enroll-
ment. As a rough rule of thumb to simplify decision making,
patients with a brain MRI scan suggestive of prion disease,
who are either able to walk (even with help) or speak some
words, should be referred promptly, particularly when clini-
cal trials are active, because these patients are highly likely
to have prion disease and MRC Scale of 5 or greater.
Although this is by far the largest study of its type, to our
knowledge, we were still underpowered to detect modifying
effects of certain factors, particularly for rare combinations
of PrPSc type and codon 129 genotype, which might be asso-
ciated with atypical clinical courses.
Biomarker analysis is a highly active area of research in
neurodegeneration and is a key component of the cohort
study. However, in prion disease, where diagnostic accuracy
(once referred) is high and progression rapid, the need for a
surrogate marker of progression is less compelling than in
slowly progressive disease syndromes. In the multivariate
analysis, standard diagnostic MRI, electroencephalography,
and CSF biomarkers did not add significantly to codon 129
subtypes for predicting the slopes of functional decline. The
analysis of quantitative MRI parameters, which seem prom-
ising as predictors of the severity of microscopic tissue
pathology, was beyond the scope of this report.25 The pro-
pensity of abnormal PrP seeds to trigger the polymerization
of PrP in vitro, for example, by the protein misfolding cyclic
amplification or real-time quaking-induced conversion
reactions,26,27 have potential as highly responsive therapeu-
tic biomarkers in CSF and will be important adjuncts to
future trials.
Conclusions
Functional end points in other neurodegenerative diseases
typically require several hundredor thousands of patients for
adequately powered studies.28 Here we established that re-
peated measurements of a functional scale in only 120 pa-
tients with prion disease has the capacity to provide an ad-
equately powered 2-arm study and that further reduction in
patient number (by 10-30) may be possible by increasing the
frequency of assessment. TheMRC Scale also has advantages
in that it is not affected by personal decisions regarding end-
of-life care (including percutaneous endoscopic gastrostomy
feeding and antibiotics), which can add substantial variation
in small trials using a survival endpoint, obscuring treatment
differences. It is nowdogmatic that commonneurodegenera-
tivedisorders share fundamentalmolecularmechanismswith
prion disease, often referred to as prion-like mechanisms.29
Immunotherapeutics and small molecules have been devel-
opedthatcanclearprion infection fromculturedneuronal cells
and cure infection or greatly impede it in vivo.5,8,9 The prog-
nosis for rapidly progressive prion disease is particularly se-
vere and theunmetneed is great, analogous to advanced can-
cer, which has proven to be a very effective test bed for novel
therapeutics.We hope that our studywill modify the view of
human prion disease as an orphan disorder futile for clinical
study into a tractable disorder for testing of therapeutics.
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